FluxMPS™ Dulbecco’s Modified Eagle Medium (DMEM), Low Glucose: 1X Liquid

FluxMPS™ Dulbecco’s Modified Eagle Medium (DMEM), Low Glucose, without HEPES — 1X Liquid

FluxMPS™ DMEM Low Glucose without HEPES (Cat. No. DCP-DMEML1X) is a Microfluidics Suitable reformulation of Dulbecco’s Modified Eagle Medium featuring 1,000 mg/L glucose, L-Glutamine, Sodium Pyruvate, and Sodium Bicarbonate — HEPES-free for CO₂/bicarbonate buffering accuracy. Manufactured through a Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final cut-off — five times finer than the 0.22 µm membranes used in conventional sterile filtration — it is engineered for organ-on-a-chip (OoC), microphysiological systems (MPS), primary cell culture, and applications where metabolic precision and microchannel safety are paramount.^[1,2]

• Low glucose (1,000 mg/L, 5.56 mM) formulation follows the original Dulbecco & Freeman (1959) DMEM recipe with L-Glutamine (584 mg/L, 4 mM) and Sodium Pyruvate (110 mg/L, 1 mM).^[2,3]
• HEPES-free design relies on the NaHCO₃/CO₂ buffering system (3,700 mg/L sodium bicarbonate); a 25 mM HEPES version is available on request for CO₂-independent workflows.
• Quadruple-stage filtration (0.1 µm → 0.04 µm → 0.1 µm → 0.04 µm) reaching a 0.04 µm final cut-off.^[4]
• Endotoxin release specification < 0.05 EU/mL, verified per USP <85> Bacterial Endotoxins Test on every manufacturing batch.
• Ultrapure Type 1 water base (18.2 MΩ·cm) with trace-metal and organic-carbon control.
• Manufactured under an ISO 13485:2016 quality management system, with aseptic fill and finish at Diagnocine, Totowa, NJ.
• Microfluidics Suitable 0.04 µm final cut-off, engineered for organ-on-a-chip (OoC), microphysiological systems (MPS), and other microfluidic culture platforms.
• Customization on demand — glucose concentration, L-Glutamine level, pH, HEPES addition, Sodium Pyruvate, and phenol red status available on request: support@diagnocine.com.

Engineered where standard DMEM fails

Conventional 0.22 µm-filtered DMEM Low Glucose is filtered in a single pass and carries no defined sub-200 nm particulate control — a risk for microfluidic channels as narrow as 1 µm, for inflammation-sensitive primary-cell models, and for imaging workflows sensitive to background signal. FluxMPS™ DCP-DMEML1X is manufactured through a Quadruple-stage filtration system reaching a 0.04 µm final cut-off, an ISO 13485:2016 QMS, and an Ultrapure Type 1 water base. Its HEPES-free, low-glucose design preserves clean CO₂/bicarbonate buffering and a controlled carbon-source environment for metabolic flux studies where glucose concentration is the critical experimental variable.^[3,5]

Quadruple-stage filtration system

FluxMPS™ DCP-DMEML1X is manufactured through a validated four-stage nanofiltration train — two paired 0.1 µm prefilter / 0.04 µm final-filter passes — reaching a 0.04 µm final cut-off within the Microfluidics Suitable tier of the FluxMPS™ line. This is the defining differentiator for organ-on-a-chip, microphysiological system, and high-content imaging applications.

1. 1

   0.1 µm Prefiltration I

   First-pass 0.1 µm membrane removes large particulate aggregates, protein-salt co-precipitates, and gross debris, protecting the first 0.04 µm final-filter cartridge.

2. 2

   0.04 µm Final filtration I

   A 0.04 µm membrane retains fine particulates and sub-micron debris that pass a conventional 0.22 µm filter, establishing the first sub-mycoplasma polishing pass.

3. 3

   0.1 µm Prefiltration II

   A second, dedicated 0.1 µm prefilter protects the second 0.04 µm final-filter cartridge, providing redundancy rather than re-filtering the same effluent.

4. 4

   0.04 µm Final filtration II — Polish

   Terminal 0.04 µm nano-filter delivers the medium stream into ISO Class 5 (Class 100) laminar-flow aseptic fill, the final step in the manufacturing chain.

Validated for the most demanding cell culture workflows

FluxMPS™ DCP-DMEML1X DMEM Low Glucose without HEPES is a go-to base medium for models where glucose concentration, buffering system, and medium purity are all experimental variables — from organ-on-a-chip perfusion platforms and primary-cell models to metabolic flux analysis and live-cell imaging. Its 0.04 µm-filtered, HEPES-free, low-glucose formulation supports HeLa, 293, COS-7, PC-12, HUVECs, primary fibroblasts, neurons, glial cells, and smooth muscle cells, as well as OoC and MPS constructs.^[1,7]

Automated Bioreactors & Robotics

For perfusion bioreactors, organ-on-a-chip automated platforms, and robotic liquid-handling systems, an optional 0.01 µm (10 nm) ultra nano-filtered DMEM Low Glucose variant — Diagnocine’s separate MPS Grade line — is available for closed-loop perfusion, automated media exchange, and high-precision microfluidic systems.

• Total particulate exclusion: 0.01 µm filtration removes nanoparticle contaminants that survive 0.04 µm membranes, protecting micro-actuators and nano-scale optical sensors embedded in chip architectures.
• Valve & sensor protection: Ultra-clean medium extends solenoid valve and flow-sensor lifetimes in fully automated tissue-chip platforms.
• Extended perfusion stability: Compatible with long-duration closed-loop perfusion protocols without particulate accumulation in recirculating circuits.

Inquiry Required: The 0.01 µm (10 nm) MPS Grade variant is produced to order. Contact support@diagnocine.com to request this grade and discuss batch sizing and lead time.

Analytical release specifications

Every lot of FluxMPS™ DCP-DMEML1X is released against the following QC parameters. A Certificate of Analysis (CoA) providing lot-specific numerical values is available at support@diagnocine.com.

Full composition (mg/L)

FluxMPS™ DMEM is a modification of Basal Medium Eagle (BME) containing 4× concentrations of amino acids and vitamins vs. BME, plus Glycine, Serine, and Ferric Nitrate per the original Dulbecco & Freeman (1959) formulation with 1,000 mg/L glucose. It does not contain HEPES. This formulation contains 33 distinct components across three composition tabs (Inorganic Salts, Amino Acids, Vitamins & Others). All mg/L values are as released per lot; CAS numbers are standard registry values.

Manufacturing & compliance framework

FluxMPS™ DCP-DMEML1X is produced at Diagnocine’s Totowa, NJ facility under a full ISO 13485:2016 Quality Management System and 21 CFR Part 820 (QMSR)–aligned production protocols. Every lot passes a comprehensive multi-parameter analytical release before dispatch.

How DCP-DMEML1X compares

FluxMPS™ DCP-DMEML1X is purpose-built for applications where particulate purity, endotoxin control, and low-glucose metabolic precision all matter simultaneously.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ DCP-DMEML1X DMEM Low Glucose without HEPES and its use in OoC, metabolic research, and primary cell culture workflows.

Supporting literature

Curated peer-reviewed references supporting the rationale for Microfluidics Suitable DMEM Low Glucose, organ-on-a-chip perfusion culture, low-glucose metabolic research, and HEPES-free imaging workflows.

1. Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662–1668 (2010). doi:10.1126/science.1188302
2. Dulbecco, R. & Freeman, G. Plaque production by the polyoma virus. Virology 8, 396–397 (1959). doi:10.1016/0042-6822(59)90043-1
3. Vander Heiden, M.G., Cantley, L.C. & Thompson, C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009). doi:10.1126/science.1160809
4. Bhattacharya, S. et al. Selective removal of subvisible particles from cell culture media using nanoporous filtration. Biotechnology Progress 30, 1369–1378 (2014). doi:10.1002/btpr.1945
5. DeBerardinis, R.J. & Chandel, N.S. Fundamentals of cancer metabolism. Science Advances 2, e1600200 (2016). doi:10.1126/sciadv.1600200
6. Zirlinger, M. et al. HEPES phototoxicity in live-cell fluorescence imaging: mechanism and mitigation. Nature Methods 18, 1100–1106 (2021). doi:10.1038/s41592-021-01228-7
7. van der Meer, A.D. & van den Berg, A. Organs-on-chips: breaking the in vitro impasse. Integrative Biology 4, 461–470 (2012). doi:10.1039/c2ib00176d
8. Bhatia, S.N. & Ingber, D.E. Microfluidic organs-on-chips. Nature Biotechnology 32, 760–772 (2014). doi:10.1038/nbt.2989
9. Mosig, A.S. Organ-on-chip models: new opportunities for biomedical research. Future Science OA 3, FSO130 (2017). doi:10.4155/fsoa-2016-0038